Powder: -20°C for 3 years | In solvent: -80°C for 1 year
BChE-IN-14 (compound 19c) can restore cognitive impairment in vivo that can be used in the Alzheimer’s disease research. BChE-IN-14 has primary cell safety and good blood brain barrier permeability. BChE-IN-14 is a selective inhibitor of butyrylcholinesterase (BChE) with IC50 values of 0.011 μM and 0.23 μM for hBChE and eqBChE, respectively [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 6-8 weeks | $ 1,520.00 | |
50 mg | 6-8 weeks | $ 1,980.00 | |
100 mg | 6-8 weeks | $ 2,500.00 |
Description | BChE-IN-14 (compound 19c) can restore cognitive impairment in vivo that can be used in the Alzheimer’s disease research. BChE-IN-14 has primary cell safety and good blood brain barrier permeability. BChE-IN-14 is a selective inhibitor of butyrylcholinesterase (BChE) with IC50 values of 0.011 μM and 0.23 μM for hBChE and eqBChE, respectively [1]. |
In vitro | BChE-IN-14, at concentrations ranging from 0.0001 to 100 μM, effectively inhibits both equine serum BChE (eqBChE) and human BChE (hBChE), with half-maximal inhibitory concentrations (IC50) of 0.23 μM and 0.011 μM, respectively [1]. |
In vivo | BChE-IN-14, administered orally at a dosage of 15 mg/kg from days 3-8 post Aβ 1-42 injection, enhances memory and cognitive functions in an Alzheimer's Disease (AD) mouse model [1]. This was observed in ICR mice injected with oligomerized Aβ 1-42 peptide [1], where BChE-IN-14 not only improved in vivo memory and cognition but also demonstrated quicker response times compared to donepezil. |
Molecular Weight | 331.49 |
Formula | C24H29N |
CAS No. | 2700896-78-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
BChE-IN-14 2700896-78-0 inhibitor inhibit